BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38316747)

  • 1. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS
    Lv Y; Yang Z; Chen Y; Ma X; Guo M; Zhang C; Jiang X; Wang C; Li Z; Tai Z; Wang X; Zhang S; Ma S; Qin C
    J Med Chem; 2024 Feb; 67(4):2487-2511. PubMed ID: 38316747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
    Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
    Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PI3Kα overcomes resistance to KRas
    Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
    Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.
    Begovich K; Schoolmeesters A; Rajapakse N; Martinez-Terroba E; Kumar M; Shakya A; Lai C; Greene S; Whitefield B; Okano A; Mali V; Huang S; Chourasia AH; Fung L
    Mol Cancer Ther; 2024 Apr; 23(4):407-420. PubMed ID: 38224565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS
    Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y
    Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-Humans PET Imaging of
    Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
    J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.
    Zhang Y; Liu L; Pei J; Ren Z; Deng Y; Yu K
    Oncogene; 2024 Feb; 43(9):668-681. PubMed ID: 38191673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 143D, a novel selective KRAS
    Xu LS; Zheng SX; Mei LH; Yang KX; Wang YF; Zhou Q; Kong XT; Zheng MY; Jiang HL; Xie CY
    Acta Pharmacol Sin; 2023 Jul; 44(7):1475-1486. PubMed ID: 36725884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined KRAS
    Thatikonda V; Lu H; Jurado S; Kostyrko K; Bristow CA; Bosch K; Feng N; Gao S; Gerlach D; Gmachl M; Lieb S; Jeschko A; Machado AA; Marszalek ED; Mahendra M; Jaeger PA; Sorokin A; Strauss S; Trapani F; Kopetz S; Vellano CP; Petronczki M; Kraut N; Heffernan TP; Marszalek JR; Pearson M; Waizenegger I; Hofmann MH
    bioRxiv; 2023 Jan; ():. PubMed ID: 36747713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
    Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
    Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
    Morimoto K; Yamada T; Hirai S; Katayama Y; Fukui S; Sawada R; Tachibana Y; Matsui Y; Nakamura R; Ishida M; Kawachi H; Kunimasa K; Sasaki T; Nishida M; Furuya N; Watanabe S; Shiotsu S; Nishioka N; Horinaka M; Sakai T; Uehara H; Yano S; Son BK; Tokuda S; Takayama K
    Cancer Lett; 2024 Apr; 587():216692. PubMed ID: 38342232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.